FdaApplication
NDA 214358
Identifiers
- fda_app_no: NDA214358
Properties
| Property | Value |
|---|---|
| applicant_name | BOEHRINGER INGELHEIM PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2021-06-21 |
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PRADAXA | DABIGATRAN ETEXILATE MESYLATE | EQ 50MG BASE/PACKET | PELLETS;ORAL |
| PRADAXA | DABIGATRAN ETEXILATE MESYLATE | EQ 110MG BASE/PACKET | PELLETS;ORAL |
| PRADAXA | DABIGATRAN ETEXILATE MESYLATE | EQ 150MG BASE/PACKET | PELLETS;ORAL |
| PRADAXA | DABIGATRAN ETEXILATE MESYLATE | EQ 30MG BASE/PACKET | PELLETS;ORAL |
| PRADAXA | DABIGATRAN ETEXILATE MESYLATE | EQ 40MG BASE/PACKET | PELLETS;ORAL |
| PRADAXA | DABIGATRAN ETEXILATE MESYLATE | EQ 20MG BASE/PACKET | PELLETS;ORAL |
6 products